Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market to Reach USD 17.19 Billion by 2030 Amid Rising Demand for Minimally Invasive Procedures

The global benign prostatic hyperplasia (BPH) surgical treatment market is experiencing steady growth, driven by the increasing prevalence of prostate enlargement among aging men, advancements in minimally invasive treatment technologies, and rising awareness of effective BPH management. Valued at USD 11.92 billion in 2023, the market reached USD 12.62 billion in 2024 and is projected to grow at a CAGR of 5.3%, reaching USD 17.19 billion by 2030.

Benign prostatic hyperplasia is one of the most common urological conditions affecting older men. The condition causes enlargement of the prostate gland, leading to urinary symptoms such as frequent urination, weak urine flow, difficulty emptying the bladder, and nighttime urination. As global life expectancy continues to increase, healthcare systems are witnessing a growing demand for advanced BPH treatment solutions that improve patient outcomes while reducing recovery time.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374

Rising Aging Population Drives the Benign Prostatic Hyperplasia Surgical Treatment Market

One of the strongest factors fueling the benign prostatic hyperplasia surgical treatment market is the rapid growth of the global geriatric population. Since the risk of developing BPH increases significantly with age, the expanding elderly population directly contributes to higher diagnosis and treatment rates.

Studies indicate that nearly half of men between the ages of 51 and 60 experience symptoms associated with benign prostatic hyperplasia, while the prevalence continues to rise among individuals over 65 years of age. As the global population aged 65 years and older continues to expand, healthcare providers are increasingly investing in effective treatment options that help improve quality of life for aging patients.

In addition, longer life expectancy and improved access to healthcare services have resulted in earlier diagnosis and greater willingness among patients to seek treatment for urinary symptoms that were previously considered a normal part of aging.

Increasing BPH Prevalence Supports Long-Term Market Growth

The global burden of benign prostatic hyperplasia has grown substantially over the past two decades. Rising life expectancy, changing lifestyles, and improved diagnostic capabilities have contributed to a significant increase in diagnosed cases worldwide.

Healthcare professionals are also observing a greater incidence of lower urinary tract symptoms associated with enlarged prostate glands, creating sustained demand for both pharmaceutical therapies and surgical interventions.

Growing awareness campaigns, improved patient education, and better screening practices are encouraging men to seek medical care earlier, allowing physicians to recommend appropriate treatment before symptoms become severe.

Obesity and Lifestyle Factors Increase Demand for BPH Treatment

The growing prevalence of obesity among men is emerging as another important contributor to the benign prostatic hyperplasia surgical treatment market.

Medical research has established a close relationship between obesity and prostate enlargement. Excess body weight contributes to several physiological changes that promote BPH development, including:

• Increased inflammation
• Hormonal imbalance
• Elevated oxidative stress
• Greater sympathetic nervous system activity
• Higher intra-abdominal pressure

As obesity rates continue to rise globally, healthcare providers are witnessing increasing numbers of patients requiring long-term BPH management, including minimally invasive surgical procedures when medication alone is insufficient.

Growing Preference for Minimally Invasive Surgical Procedures

One of the most significant trends transforming the BPH treatment landscape is the increasing adoption of minimally invasive surgical procedures.

Patients today prefer treatments that provide:

• Faster recovery
• Reduced hospital stays
• Less postoperative pain
• Lower complication rates
• Improved quality of life
• Faster return to normal activities

Innovative technologies such as laser therapy, UroLift, Rezūm water vapor therapy, robotic waterjet ablation, and prostatic artery embolization are expanding treatment options beyond traditional surgery.

These advanced procedures are helping physicians deliver highly effective treatment while minimizing complications associated with conventional surgical techniques.

As hospitals continue investing in advanced urology equipment, minimally invasive BPH procedures are expected to witness strong adoption across developed and emerging healthcare markets.

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374

Market Ecosystem Continues to Expand

The benign prostatic hyperplasia surgical treatment market ecosystem includes pharmaceutical manufacturers, medical device companies, distributors, healthcare providers, hospitals, specialty urology clinics, and research organizations.

Pharmaceutical companies continue investing in improved drug therapies that manage urinary symptoms and delay disease progression, while medical technology companies are introducing innovative surgical systems designed to improve precision, reduce complications, and shorten recovery time.

Distributors play a critical role in expanding product availability, while leading hospitals and specialty clinics continue adopting advanced technologies that enhance patient care and procedural efficiency.

Alpha-Blockers Hold the Largest Drug Segment

Based on drug type, alpha-blockers accounted for the largest share of the global BPH treatment market in 2023.

These medications remain the preferred first-line therapy for many patients because they rapidly relax smooth muscles around the bladder neck and prostate, improving urine flow and reducing urinary obstruction.

Their widespread clinical acceptance, favorable treatment outcomes, and extensive physician familiarity continue to support their leading market position.

Other pharmaceutical treatment options, including 5-alpha reductase inhibitors, also contribute significantly by reducing prostate size and slowing disease progression in appropriate patient populations.

TURP Continues to Remain the Gold Standard Procedure

Among treatment procedures, Transurethral Resection of the Prostate (TURP) continues to represent one of the most widely performed surgical interventions for benign prostatic hyperplasia.

TURP remains the preferred treatment for moderate to severe BPH because of its long-established clinical effectiveness, reliable patient outcomes, and cost efficiency.

Despite the emergence of several minimally invasive alternatives, TURP continues to be regarded as the gold standard surgical procedure for prostate tissue removal.

Alongside TURP, newer technologies gaining widespread adoption include:

• Laser prostate surgery
• UroLift System
• Rezūm water vapor therapy
• Robot-assisted waterjet ablation
• Prostatic artery embolization
• Prostatic stenting
• Transurethral microwave thermotherapy (TUMT)
• Transurethral needle ablation (TUNA)

The growing availability of multiple treatment options allows physicians to personalize therapy based on prostate size, patient health, and symptom severity.

North America Leads the Global Market

North America accounted for the largest share of the benign prostatic hyperplasia surgical treatment market in 2023.

The region benefits from several competitive advantages, including:

• Advanced healthcare infrastructure
• Strong reimbursement systems
• High patient awareness
• Early adoption of innovative treatment technologies
• Availability of experienced urologists
• Continuous investment in minimally invasive surgical platforms

The increasing utilization of advanced procedures such as UroLift, Rezūm therapy, robotic waterjet ablation, and prostatic stenting has further strengthened North America's leadership position.

Meanwhile, Asia Pacific is expected to witness significant future growth due to improving healthcare infrastructure, expanding elderly populations, rising healthcare spending, and increasing awareness of advanced urological care.

Competitive Landscape

The global benign prostatic hyperplasia surgical treatment market is characterized by continuous innovation, strategic collaborations, and product development. Companies are focusing on expanding their portfolios through advanced pharmaceuticals, minimally invasive surgical technologies, and robotic-assisted treatment platforms.

Leading market participants include GlaxoSmithKline PLC, Eli Lilly and Company, Astellas Pharma Inc., Viatris Inc., Asahi Kasei Corporation, Organon & Co., Alembic Pharmaceuticals Limited, Teleflex Incorporated, Boston Scientific Corporation, Olympus Corporation, PROCEPT BioRobotics Corporation, Coloplast Group, IPG Photonics Corporation, ProstaLund AB, KARL STORZ SE & Co. KG, Richard Wolf GmbH, and Quanta System.

These organizations continue investing in research and development to improve clinical outcomes while addressing the growing demand for safe, effective, and patient-friendly BPH treatment solutions.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=198000374

Future Outlook

The future of the benign prostatic hyperplasia surgical treatment market remains highly promising. Rising life expectancy, increasing obesity rates, expanding healthcare access, and continuous technological innovation are expected to sustain long-term market growth through 2030.

As healthcare providers increasingly prioritize minimally invasive therapies that deliver superior patient outcomes with shorter recovery periods, demand for advanced BPH surgical treatments will continue to accelerate. Supported by favorable healthcare investments, expanding treatment options, and growing awareness among patients, the global BPH surgical treatment market is well positioned for sustained growth in the coming years.